Novo Nordisk Weight Loss Drug Cuts Heart Disease Risk By 20%

Like
Comment
Favorite

Novo Nordisk Weight Loss Drug Cuts Heart Disease Risk By 20%

seekingalpha2023-08-08

Novo Nordisk announced Tuesday that its weight loss therapy semaglutide led to a 20% reduction in adverse cardiovascular events in a Phase 3 trial for obese or overweight adults with cardiovascular ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

No comments yet

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/1132311155?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2023-08-08 18:54","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"1132311155","market":"us","top_or_hot":-1,"title":"Novo Nordisk Weight Loss Drug Cuts Heart Disease Risk By 20%","media":"seekingalpha","content":"<div>\n<p>Novo Nordisk  announced Tuesday that its weight loss therapy semaglutide led to a 20% reduction in adverse cardiovascular events in a Phase 3 trial for obese or overweight adults with cardiovascular ...</p>\n\n<a href=\"https://seekingalpha.com/news/3998866-novo-nordisk-weight-loss-drug-cuts-heart-disease-risk\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novo Nordisk Weight Loss Drug Cuts Heart Disease Risk By 20%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovo Nordisk Weight Loss Drug Cuts Heart Disease Risk By 20%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-08-08 18:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3998866-novo-nordisk-weight-loss-drug-cuts-heart-disease-risk><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Novo Nordisk  announced Tuesday that its weight loss therapy semaglutide led to a 20% reduction in adverse cardiovascular events in a Phase 3 trial for obese or overweight adults with cardiovascular ...</p>\n\n<a href=\"https://seekingalpha.com/news/3998866-novo-nordisk-weight-loss-drug-cuts-heart-disease-risk\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVO","symbol_name":"诺和诺德","start_time":0,"source_url":"https://seekingalpha.com/news/3998866-novo-nordisk-weight-loss-drug-cuts-heart-disease-risk","article_id":"1132311155","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1132311155","pubTimestamp":1691492071,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"$Novo Nordisk (NVO)$ announced Tuesday that its weight loss therapy semaglutide led to a 20% reduction in adverse cardiovascular events in a Phase 3 trial for obese or overweight adults with cardiovas","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"NVO":"诺和诺德"},"translate_title":"诺和诺德减肥药降低心脏病风险20%","themeId":"c5bbfdf5f7964880af97c1d6f417052c","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":1.1},"content_text":"Novo Nordisk  announced Tuesday that its weight loss therapy semaglutide led to a 20% reduction in adverse cardiovascular events in a Phase 3 trial for obese or overweight adults with cardiovascular disease.The topline results from the company’s SELECT cardiovascular outcomes trial sent Novo Nordisk (NVO) ADRs ~13% higher in the pre-market. Novo’s closest rival in the weight loss space, Eli Lilly , added ~8%.The SELECT study involved more than 17,000 adults aged 45 years and older who didn’t have a prior history of diabetes. In addition to standard of care, they received semaglutide 2.4 mg or placebo for the prevention of major adverse cardiovascular events.According to the company, semaglutide, branded as Wegovy for weight loss, achieved its primary objective as those who received the treatment indicated a statistically significant 20% reduction of MACE compared to those on placebo over a period of up to five years.\"SELECT is a landmark trial and has demonstrated that semaglutide 2.4 mg has the potential to change how obesity is regarded and treated,\" Martin Holst Lange, Novo’s (NVO) executive vice president for development, said.The company expects to share detailed data from the trial at a medical conference later this year and plans to seek regulatory approvals for a label expansion of Wegovy in 2023.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}